Senior Director
Mineralys Therapeutics
Senior Director
Mineralys Therapeutics
Clinical-stage biopharma targeting aldosterone synthesis
“Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky”
Mineralys is a fully remote company.
Position Summary
The Senior Director, Analytical Sciences provides strategic and technical leadership for analytical activities supporting the development, registration, validation, launch, and lifecycle management of the company's small molecule drug substance and drug product portfolio. The role is accountable for analytical development, method lifecycle management, specification setting, stability programs, regulatory support, and oversight of external analytical laboratories, contract development and manufacturing organizations (CDMOs), and testing partners.
As a key member of the CMC leadership team, this individual establishes and executes phase-appropriate analytical strategies across all stages of development and commercialization while ensuring alignment with quality, regulatory, manufacturing, supply, and business objectives.
Key Responsibilities
Qualifications
Travel
This position is eligible for standard Company benefits including medical, dental, vision, time off and 401K, as well as participating in Mineralys incentive plans are contingent on achievement of personal and company performance. Actual compensation may vary from posted hiring range based on geographic location, work experience, education, and/or skill level.
US Salary Range: $215,000-$240,000
#LI-Remote
Clinical-stage biopharma targeting aldosterone synthesis
Mineralys Therapeutics develops targeted treatments for diseases driven by dysregulated aldosterone, aiming to control blood pressure and prevent organ damage, led by lorundrostat. Lorundrostat is an oral aldosterone synthase inhibitor that blocks the CYP11B2 enzyme to lower aldosterone production, designed to reduce blood pressure with minimal cortisol disruption due to high selectivity. Compared with older non-selective MRAs, it lowers side effects by focusing on aldosterone synthesis rather than receptor blockade. The company's goal is to advance lorundrostat through late-stage trials toward regulatory approval and commercialization, while exploring expanded uses in CKD and OSA for a potential multi-hundred-billion market.
Explore more opportunities at Mineralys Therapeutics